AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 65(5), 2001, pp. 471-476
Copyright © 2001 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duarte, E.
Right arrow Articles by Fontes, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duarte, E.
Right arrow Articles by Fontes, C.
Related Collections
Right arrow Travel Medicine
Right arrow Malaria
American Journal of Tropical Medicine and Hygiene, Vol 65, Issue 5, 471-476
Copyright © 2001 by American Society of Tropical Medicine and Hygiene

Research Articles


Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria

EC Duarte, LW Pang, LC Ribeiro, and CJ Fontes

This study evaluated the cure rate of the standard recommended regimen for Plasmodium vivax malaria in Brazil and assessed risk factors for failures. Fifty patients with vivax malaria given supervised medical treatment (standard dose of chloroquine: total dose = 1.5 g over a three-day period plus primaquine: total dose = 210 mg over a 14-day period) were followed for six months in a non-endemic area. Cox's regression was used to identify predictors of relapses. Among the 289 patient-months of follow-up, seven relapses were identified (2.4 relapses per 100 person-months) between 33 and 137 days after treatment initiation. Risk factors for relapses (P < or = 0.05) were female sex, higher parasitemia at baseline, shorter number of days with symptoms prior to baseline, and lower mg/kg dose of primaquine. Relapses following supervised vivax treatment is in principle a necessary, but not sufficient, component of in vivo parasite resistance. Results indicate that other factors, principally sub-therapeutic primaquine doses, may explain the occurrence of vivax treatment failures.


This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
J. L. GOLLER, D. JOLLEY, P. RINGWALD, and B.-A. BIGGS
REGIONAL DIFFERENCES IN THE RESPONSE OF PLASMODIUM VIVAX MALARIA TO PRIMAQUINE AS ANTI-RELAPSE THERAPY
Am J Trop Med Hyg, February 1, 2007; 76(2): 203 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. ALVAREZ, J.-G. PINEROS, A. TOBON, A. RIOS, A. MAESTRE, S. BLAIR, and J. CARMONA-FONSECA
Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
Am J Trop Med Hyg, October 1, 2006; 75(4): 605 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. R. HILL, J. K. BAIRD, M. E. PARISE, L. S. LEWIS, E. T. RYAN, and A. J. MAGILL
PRIMAQUINE: REPORT FROM CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS I.
Am J Trop Med Hyg, September 1, 2006; 75(3): 402 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
J. M. Spudick, L. S. Garcia, D. M. Graham, and D. A. Haake
Diagnostic and Therapeutic Pitfalls Associated with Primaquine-Tolerant Plasmodium vivax
J. Clin. Microbiol., February 1, 2005; 43(2): 978 - 981.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Tropical Medicine and Hygiene.